# Andreas du Bois

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/andreas-du-bois/

## Facts

| Field | Value |
| --- | --- |
| Citations | 36,786 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 89 |
| i10-index | 362 |
| Last Known Institution | Kliniken Essen-Mitte |
| OpenAlex ID | https://openalex.org/A5047695952 |
| ORCID iD | https://orcid.org/0000-0002-8477-506X |
| Works | 903 |

## Researcher papers

Showing 12 of 15.

- [A Phase 3 Trial of Bevacizumab in Ovarian Cancer](https://scholariq.org/papers/a-phase-3-trial-of-bevacizumab-in-ovarian-cancer/)
- [ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease](https://scholariq.org/papers/esmo-esgo-consensus-conference-recommendations-on-ovarian-cancer-pathology-and/)
- [Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk](https://scholariq.org/papers/common-genetic-variation-in-cellular-transport-genes-and-epithelial-ovarian/)
- [A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms](https://scholariq.org/papers/a-randomized-trial-of-lymphadenectomy-in-patients-with-advanced-ovarian/)
- [Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study](https://scholariq.org/papers/neoadjuvant-treatment-with-trastuzumab-in-her2-positive-breast-cancer-results/)
- [Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial](https://scholariq.org/papers/surgery-in-recurrent-ovarian-cancer-the-arbeitsgemeinschaft-gynaekologische/)
- [GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer](https://scholariq.org/papers/gwas-meta-analysis-and-replication-identifies-three-new-susceptibility-loci-for/)
- [Treatment of recurrent ovarian cancer](https://scholariq.org/papers/treatment-of-recurrent-ovarian-cancer/)
- [Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer](https://scholariq.org/papers/prospective-validation-study-of-a-predictive-score-for-operability-of-recurrent/)
- [Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group](https://scholariq.org/papers/borderline-tumours-of-the-ovary-a-cohort-study-of-the-arbeitsgemeinschaft/)
- [Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase](https://scholariq.org/papers/operability-and-chemotherapy-responsiveness-in-advanced-low-grade-serous-ovarian/)
- [Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 Study](https://scholariq.org/papers/adjuvant-therapy-in-lymph-node-positive-vulvar-cancer-the-ago-care-1-study/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Intraperitoneal and Appendiceal Malignancies](https://scholariq.org/topics/intraperitoneal-and-appendiceal-malignancies/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [Kliniken Essen-Mitte](https://scholariq.org/institutions/kliniken-essen-mitte/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.